LONDON, UK and ATLANTA, US, May 14, 2007 - SkyePharma PLC (LSE:SKP; NASDAQ:SKYE) and Sciele Pharma. Inc. (NASDAQ: SCRX) today announce the successful completion of the clinical trial programme for the new formulation of Sular®, a calcium channel blocking agent for the treatment of high blood pressure. The study results showed that the new Sular formulation is bioequivalent to Sciele’s currently marketed Sular. The new Sular formulation utilizes SkyePharma’s patented GeomatrixTM technology, which is designed to provide a lower dose of Sular for each of its current doses.
